Haemonetics Corporation
$5.68B- Market cap
- $4.68B
- Debt
- +$1.24B
- Cash
- −$245.44M
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.58x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: HAE stock price vs TFX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TFX's multiple
Needs TFX P/E.
Implied fair value · at HAE's multiple
Needs EPS (TTM) is negative, HAE P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HAE FY 2026 (ended Mar 28, 2026) · TFX FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 79% equity / 21% debt · EV / Revenue 4.26x · EV / EBITDA 21.58x
Capital structure 68% equity / 32% debt · EV / Revenue 4.11x
TFX carries the larger enterprise value at $8.19B against $5.68B; TFX trades on the lower EV / Revenue multiple (4.11x vs 4.26x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Haemonetics Corporation · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
TELEFLEX INCORPORATED · implied price per share
Bear
-$24.97
Base
-$21.78
Bull
-$16.12
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.56x
0.88x
Net debt / EBITDA
Leverage against operating earnings
3.80x
-3.63x
Cash and equivalents
Liquid reserves on the balance sheet
$245.44M
$411.39M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
BECTON DICKINSON & CO
HAE vs BDX
BAXTER INTERNATIONAL INC
HAE vs BAX
LivaNova PLC
HAE vs LIVN
STERIS plc
HAE vs STE
ABBOTT LABORATORIES
HAE vs ABT
BOSTON SCIENTIFIC CORP
HAE vs BSX
Medtronic plc
HAE vs MDT
STRYKER CORP
HAE vs SYK
DENTSPLY SIRONA Inc.
HAE vs XRAY
RESMED INC
HAE vs RMD
$1.24B
$2.74B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.